Arrhythmia

A cost-effectiveness analysis of the EAST – AFNET 4 trial indicated the health benefits of early rhythm control come at reasonable additional costs compared to usual care.

The latest cardiology case report from Brady Pregerson, MD, features a woman in her 80s presenting with complaints of atrial fibrillation for multiple days. Can you determine the correct diagnosis?

The randomized AWARE trial indicates patients with paroxysmal AF did not have improved freedom from recurrent atrial arrhythmia with a double ablation lesion set compared with a single procedure.

In an interview at ACC 2023, Harrington elaborated on the upcoming phase 3 Librexia clinical trial program studying the Factor XIa inhibitor for the prevention of thrombotic events.

New data from a predefined secondary analysis of the STROKE-AF trial provides insight into the 3-year incidence of atrial fibrillation among patients with a history of ischemic stroke caused by atherosclerosis.

On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.

Results from the ACTIVE-AF trial indicate participation in an exercise-based intervention reduced arrhythmia recurrence and improved symptom severity among patients with AF.

At 12 months of the CAPLA trial, the addition of posterior wall isolation to pulmonary vein isolation led to no significant improvements in freedom from atrial arrhythmia.

Patients with AF experienced worse 90-day outcomes than those without AF, even with comparable, successful reperfusion outcomes.

An analysis of data from Medicare beneficiaries receiving treatment over a decade-long period provides a snapshot of oral anticoagulation initiation and nonadherence among older patients with atrial fibrillation in the US.

Using data from 88 medical centers across the US, new data is providing clinicians with an overview of contemporary trends in DOAC and warfarin use in adult patients with nonvalvular atrial fibrillation at high risk for stroke over the past decade.

A comparative analysis leveraging EHR data from more than 500k new DOAC users from Europe and the US suggests apixaban use was associated with the lowest risk of gastrointestinal bleeding among agents within the class, with similar rates of thromboembolic events and mortality observed among the class.

An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.

An analysis of data from linked national registries in Sweden provides clinicians with new insight into the impact of early life BMI on cardiovascular risk, particularly risk of atrial fibrillation, later in life among men.

An analysis of claims data from a 7-year period provides insight into the rate of ischemic stroke or systemic embolism and bleeding events with 2 popular DOACs in people with atrial fibrillation and valvular heart disease.

Announced by Boston Scientific on September 6, the label for the WATCHMAN FLX LAAC device now includes a 45-day DAPT option as an alternative to the 45-day postprocedural OAC plus aspirin regimen for patients with nonvalvular atrial fibrillation.

Despite the notion that men were at greater risk than women for developing AFib, new research indicates women were at a 49% greater risk of developing AFib than their male counterparts of the same height and weight.

An analysis of Danish national register data suggests patients using medical cannabis for pain had a 64% greater risk of arrhythmias than their unexposed counterparts.

Data from the SMART WARS study provides insight into the diagnostic utility of the KardiaBand and Apple Watch Series 4 devices for detecting arrhythmias in older adults.

Results of DECAAF II, an RCT assessing MRI-guided ablation plus PVI to PVI alone for persistent AFib, suggest the more aggressive approach did not result in a statistically significant difference in arrhythmia recurrence but was associated with increased occurrence of safety events, including stroke.

A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.

Solomon Sager, MD, shares his experience using ICMs in clinical practice for patients with atrial fibrillation and syncope.

An expert in cardiovascular medicine provides insight on long-term monitoring solutions in the pipeline for the management of atrial fibrillation and syncope.

Dr. Solomon Sager assesses the benefit of earlier ICM use on patients and providers for the management of atrial fibrillation and syncope.

A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.